Access Statistics for Mary K. Olson

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Pharmaceutical Expenditure and Regulatory Policy in the NHS 0 0 0 0 0 0 0 332
Total Working Papers 0 0 0 0 0 0 0 332


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Agency Rulemaking, Political Influences, Regulation, and Industry Compliance 0 0 0 0 0 0 1 361
Are novel drugs more risky for patients than less novel drugs? 0 0 0 29 0 0 8 120
Eliminating the U.S. drug lag: Implications for drug safety 0 0 0 13 5 7 8 116
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 1 1 1 3 1 4 8 25
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity 0 0 0 7 2 4 6 62
Firm Characteristics and the Speed of FDA Approval 0 1 1 42 1 3 4 145
New clinical information and physician prescribing: How do pediatric labeling changes affect prescribing to children? 0 0 0 3 2 2 2 31
Pharmaceutical Policy Change and the Safety of New Drugs 0 1 2 9 0 2 7 72
Political Influence and Regulatory Policy: The 1984 Drug Legislation 0 0 0 0 1 3 3 179
Reassessing the impact of health IT: Hidden costs and consequences of vendor heterogeneity 0 1 2 2 6 8 16 16
Regulatory Agency Discretion among Competing Industries: Inside the FDA 0 0 0 0 1 2 5 192
Regulatory Reform and Bureaucratic Responsiveness to Firms: the Impact of User Fees in the FDA 0 0 0 25 3 6 8 128
Substitution in Regulatory Agencies: FDA Enforcement Alternatives 0 0 0 0 1 1 1 201
The Effects of UK Pharmaceutical Policy on Government Drug Expenditure: Cost Control and Incentives for R&D 0 0 0 12 0 1 2 71
The risk we bear: The effects of review speed and industry user fees on new drug safety 0 2 2 28 2 4 5 141
Total Journal Articles 1 6 8 173 25 47 84 1,860


Statistics updated 2026-01-09